Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epoetin alfa or beta
- Development stage
- Approved
- Lead developer
- Amgen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Epoetin alfa and epoetin beta are recombinant forms of human erythropoietin (rHuEPO), a glycoprotein hormone that stimulates the bone marrow to produce red blood cells. These agents are classified as erythropoiesis-stimulating agents (ESAs) and are used primarily to treat anemia associated with chronic kidney disease (CKD), chemotherapy-induced anemia in cancer patients, and anemia related to zidovudine treatment in HIV-infected individuals. They may also be used perioperatively to reduce the need for allogeneic blood transfusions in certain surgical patients. Epoetins act by binding to the erythropoietin receptor on erythroid progenitor cells in the bone marrow, promoting their survival and differentiation into mature red blood cells[1][2][3][5]. Both drugs have similar mechanisms of action but differ slightly in their molecular structure and pharmacokinetics.
- Brand names
- EpogenProcritRetacritNeoRecormonEprex
- Other names
- recombinant human erythropoietinrHuEPO
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on epoetin alfa or beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epoetin alfa or beta.